The Typhoid Vaccine Acceleration Consortium (TyVAC) is a partnership between the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an international nonprofit organization. TyVAC aims to accelerate the introduction of new typhoid conjugate vaccines (TCVs) as part of an integrated approach to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance.
TyVAC employs a multidisciplinary approach, working with global and local partners to accelerate the introduction of TCVs in low-income countries and facilitate access to typhoid vaccines as part of an integrated prevention plan that also includes improved water, sanitation, and hygiene. We work to ensure that typhoid prevention and control are global health priorities and that stakeholders and decision-makers have the data and tools they need to make evidence-based decisions for TCV introduction.
Dr. Kathleen Neuzil, Center for Vaccine Development
Project Director Dr. Kathleen Neuzil (CVD) is a globally recognized vaccinologist with proficiency ranging from epidemiology, international field trials, and vaccine policy, to partnerships with emerging manufacturers and direct experience with Gavi processes, World Health Organization (WHO) policy, and prequalification. She has led successful multiyear, multisite efforts in global health, informing vaccine policy recommendations and catalyzing introductions. She brings a fresh perspective and the objective approach necessary to mobilize the field and move TCVs forward.
Dr. Andrew Pollard, Oxford University
Working closely with Dr. Neuzil is Deputy Director, Dr. Andrew Pollard (Oxford), who is one of the leading typhoid experts in the world. Dr. Pollard brings considerable technical knowledge and experience in coordination of international typhoid networks and consortia. Dr. Pollard is the Director of the Oxford Vaccine Group. He chairs the United Kingdom’s National Immunization Technical Advisory Group, the European Medicines Agency’s vaccine Scientific Advisory Group, and is a WHO Strategic Advisory Group of Experts member, bringing the knowledge and expertise necessary to lead and deliver on this complex project.
Dr. Emmanuel Mugisha, PATH
Dr. Emmanuel Mugisha (PATH), based in Kampala, Uganda, leads PATH’s objectives of the TyVAC project. Dr. Mugisha has nearly 30 years of public health and management experience, including work in HIV, HPV, vaccine clinical trials, vaccine introduction, and vaccine technical support. His work has spanned the African region. Dr. Mugisha leverages his leadership and expertise to increase uptake of TCVs as part of an integrated approach to typhoid prevention and control.
TyVAC is funded by the Bill & Melinda Gates Foundation. To learn more, visit www.medschool.umaryland.edu/CVD/TyVAC.